MYD88 Deficiency
|
0.760 |
Biomarker
|
disease |
BEFREE |
Together, our results highlight the importance of epithelial-specific MyD88 signaling and demonstrate that although functional MyD88 signaling in DC and macrophages alone is sufficient to correct the phenotype of MyD88-deficiency, these cells do not seem to be essential for host protection in MyD88-sufficient animals during acute infection with C. difficile.
|
30802297 |
2019 |
MYD88 Deficiency
|
0.760 |
Biomarker
|
disease |
BEFREE |
While myeloid differentiation factor 88 (MyD88) is also a crucial adaptor for most TLR signaling pathways, MyD88 deficiency had only a marginal impact on disease course.
|
29568058 |
2018 |
MYD88 Deficiency
|
0.760 |
Biomarker
|
disease |
BEFREE |
All these responses were abrogated in mice with a general deficiency of MyD88 but unaltered in mice with MyD88 deficiency, specifically in myeloid or type II lung epithelial cells.
|
27625307 |
2017 |
MYD88 Deficiency
|
0.760 |
Biomarker
|
disease |
BEFREE |
The comparison of disease development in mice carrying the hematopoietic cell-specific deletion of MyD88 (<i>Myd88<sup>fl/fl</sup>Vav-cre<sup>+</sup></i> mice) with mice carrying the total MyD88 deficiency (<i>Myd88</i><sup>-/-</sup> mice), we show that the progression of skin and systemic inflammation, as well as of epidermal thickening, was completely dependent on MyD88 expression in hematopoietic cells.
|
28642279 |
2017 |
MYD88 Deficiency
|
0.760 |
GeneticVariation
|
disease |
UNIPROT |
Functional assessment of the mutational effects of human IRAK4 and MyD88 genes.
|
24316379 |
2014 |
MYD88 Deficiency
|
0.760 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
MYD88 L265P somatic mutation in IgM MGUS.
|
23215570 |
2012 |
MYD88 Deficiency
|
0.760 |
Biomarker
|
disease |
BEFREE |
Because MyD88 is essential for the downstream signaling of all TLRs, except TLR3, we investigated the effects of MyD88 deficiency (MyD88-/-) on behavioral functions in mice.
|
22051943 |
2012 |
MYD88 Deficiency
|
0.760 |
GeneticVariation
|
disease |
UNIPROT |
Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency.
|
21057262 |
2010 |
MYD88 Deficiency
|
0.760 |
GeneticVariation
|
disease |
UNIPROT |
Structural basis for the multiple interactions of the MyD88 TIR domain in TLR4 signaling.
|
19506249 |
2009 |
MYD88 Deficiency
|
0.760 |
GermlineCausalMutation
|
disease |
ORPHANET |
Pyogenic bacterial infections in humans with MyD88 deficiency.
|
18669862 |
2008 |
MYD88 Deficiency
|
0.760 |
Biomarker
|
disease |
BEFREE |
As MyD88(-/-) BMDM exhibit low surface expression of dectin-1 after in vitro culture in rMCSF, differences in dectin-1 dependent, MyD88-independent signaling may account for some of the phenotypes currently ascribed to MyD88-deficiency alone.
|
17997408 |
2008 |
MYD88 Deficiency
|
0.760 |
GeneticVariation
|
disease |
UNIPROT |
Pyogenic bacterial infections in humans with MyD88 deficiency.
|
18669862 |
2008 |
MYD88 Deficiency
|
0.760 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
MYD88 Deficiency
|
0.760 |
Biomarker
|
disease |
CTD_human |
|
|
|
MYD88 Deficiency
|
0.760 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, in this small case series we showed that MYD88 L265P mutation analysis could serve as a useful adjunct in distinguishing benign from lymphomatous PE in patients with LPL.
|
31556196 |
2019 |
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The diagnosis of Waldenström Macroglobulinaemia (WM)/lymphoplasmacytic lymphoma (LPL) remains one of exclusion because other B-cell lymphoproliferative disorders (B-LPD), such as marginal zone lymphoma (MZL), can fulfil similar criteria, including MYD88 L265P mutation.
|
30198568 |
2019 |
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The diagnosis of WM is established by the presence of lymphoplasmacytic lymphoma in the bone marrow or other organs, a monoclonal IgM paraproteinemia and the recurrent MYD88 L265P somatic mutation.
|
31591468 |
2019 |
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Characteristics of Waldenström Macroglobulinemia in Korean Patients According to Mutational Status of MYD88 and CXCR4: Analysis Using Ultra-Deep Sequencing.
|
31221512 |
2019 |
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The mutation profile of MYD88 genes was evaluated by Sanger sequencing in a cohort of 97 patients [DLBCL (N=55), non-DLBCL lymphomas (N=30), reactive lymphadenopathy (N=10), and 2 cases of lymphoplasmacytic lymphoma (positive control)].
|
29734251 |
2019 |
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
<i>Results</i>: MYD88 L265P mutations were detected in 22 of 29 samples from 14 patients with diffuse large B-cell lymphomas and one patient with lymphoplasmacytoid lymphoma.
|
31603365 |
2019 |
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Detection of MYD88 L265P mutation by next-generation deep sequencing in peripheral blood mononuclear cells of Waldenström's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance.
|
31483817 |
2019 |
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
MYD88 mutation has been reported in various lymphomas, specifically in lymphoplasmacytic lymphoma.
|
31576141 |
2019 |
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia.
|
30183082 |
2019 |
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders.
|
31276195 |
2019 |